Last reviewed · How we verify
Relative Bioavailability of Two Orally Administered CBD Formulations in Healthy Male Adults
This project is aimed at understanding whether a new fast-dissolving cheek-administered cannabidiol strip will be absorbed better into the body than cannabidiol powder. The results of this study will help guide dosage formulation choices as well as dosing regimens in NFL athletes for concussion management.
Details
| Lead sponsor | University of Saskatchewan |
|---|---|
| Phase | Phase 1 |
| Status | RECRUITING |
| Enrolment | 20 |
| Start date | 2024-10-26 |
| Completion | 2025-11 |
Conditions
- Pharmacokinetics
Interventions
- Cannabidiol
- Cannabidiol
Primary outcomes
- Pharmacokinetic Parameters — 1 week of samples will be collected. 2 week washout. Then another week of samples after cross over
relative bioavailability (F) - Pharmacokinetic Parameters — 1 week of samples will be collected. 2 week washout. Then another week of samples after cross over
time to maximum plasma concentration (Tmax) - Pharmacokinetic Parameters — 1 week of samples will be collected. 2 week washout. Then another week of samples after cross over
maximum plasma concentration (Cmax) - Pharmacokinetic Parameters — 1 week of samples will be collected. 2 week washout. Then another week of samples after cross over
log-linear terminal phase rate constant (k) - Pharmacokinetic Parameters — 1 week of samples will be collected. 2 week washout. Then another week of samples after cross over
area under the plasma concentration versus time curve (AUC) - Pharmacokinetic Parameters — 1 week of samples will be collected. 2 week washout. Then another week of samples after cross over
absorption rate constant (ka)
Countries
Canada